DRMA - Latest News

Dermata Therapeutics, Inc. (DRMA), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $886,024. Beta to the broader market is 0.67.

The article list below shows the most recent DRMA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent DRMA Headlines

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026

accessnewswire.com - May 13, 2026

- Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products - - Dermata plans to launch its first DTC product, the

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System

accessnewswire.com - Apr 2, 2026

- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers - - The Company also

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025

accessnewswire.com - Mar 26, 2026

- Dermata announced a strategic pivot to develop and commercialize direct-to-consumer ("DTC") skincare products under the brand name Tome - - Dermata

Head-To-Head Review: Pliant Therapeutics (NASDAQ:PLRX) versus Dermata Therapeutics (NASDAQ:DRMA)

defenseworld.net - Mar 21, 2026

Dermata Therapeutics (NASDAQ: DRMA - Get Free Report) and Pliant Therapeutics (NASDAQ: PLRX - Get Free Report) are both small-cap medical companies, b

Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing

accessnewswire.com - Mar 10, 2026

- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand - SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / Dermata

How News Affects DRMA Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track DRMA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked DRMA news questions

What is the latest DRMA news headline?

The most recent DRMA headline (May 13, 2026) is "Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the DRMA news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What DRMA news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual DRMA options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.